SCHEMBL6318813

SCHEMBL6318813

CNC(=O)[C@@H](Cc1ccc(F)cc1)N(C)C(=O)[C@@H](Cc1ccc2ccccc2c1)NC

nearest known ligand 0.47

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
MMP9 P14780 3/20 0.47
MMP8 P22894 2/20 0.47
FCER2 P06734 2/20 0.46
MC4R P32245 11/20 0.45
MC3R P41968 11/20 0.45
MC1R Q01726 11/20 0.45
F2 P00734 1/20 0.43
MMP2 P08253 1/20 0.43
TACR1 P25103 1/20 0.42
MMP3 P08254 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4427112 0.93 FCER2 (0.53) MMP9MMP8FCER2F2MMP2
SCHEMBL4426088 0.93 FCER2 (0.53) MMP9MMP8FCER2F2MMP2
SCHEMBL6317992 0.93 FCER2 (0.53) MMP9MMP8FCER2F2MMP2
SCHEMBL6320769 0.91 MMP9 (0.46) MMP9MMP8FCER2F2MMP2
SCHEMBL8711092 0.90 MMP9 (0.47) MMP9MMP8FCER2F2MMP2
SCHEMBL8905784 0.89 MMP1 (0.48) MMP9MMP8FCER2F2MMP2
SCHEMBL6318805 0.88 MC3R (0.46) MMP9MMP8FCER2MC4RMC3R
SCHEMBL6316968 0.88 MMP9 (0.45) MMP9MMP8FCER2F2MMP2
SCHEMBL6317658 0.88 MMP9 (0.45) MMP9MMP8FCER2F2MMP2
SCHEMBL7061723 0.88 GHSR (0.47) MMP9MMP8FCER2MC4RMC3R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-1997023508-A1 COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES NOVO NORDISK A/S (DK) 1997-07-03 WO claimed
US-6939880-B2 Compounds with growth hormone releasing properties NOVO NORDISK A/S (DK) 2005-09-06 US disclosed
US-6555570-B2 Growth hormone secretagogous with improved bioavailability NOVO NORDISK A/S (DE) 2003-04-29 US disclosed
US-20030055261-A1 Compounds with growth hormone releasing properties HELSINN THERAPEUTICS (U.S.), INC. 2003-03-20 US disclosed
US-20030040483-A1 Compounds with growth hormone releasing properties HELSINN THERAPEUTICS (U.S.), INC. 2003-02-27 US disclosed
US-6127391-A A PEPTIDE MIMETIC COMPOUND FOR STIMULATING THE RELEASE OF GROWTH HORMONE FROM THE PITUITARY NOVO NORDISK A/S (DK) 2000-10-03 US disclosed
US-5977178-A Compounds with growth hormone releasing properties NOVO NORDISK A/S (DK) 1999-11-02 US disclosed
EP-0907374-A1 GROWTH HORMONE COMPONENT AND BONE ANTI-RESORPTIVE AGENT IN CYCLIC (COHERENCE) TREATMENT OF OSTEOPOROSIS NOVO NORDISK A/S (DK) 1999-04-14 EP disclosed
EP-0869974-A1 COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES NOVO NORDISK A/S (DK) 1998-10-14 EP disclosed
WO-1997046252-A1 GROWTH HORMONE COMPONENT AND BONE ANTI-RESORPTIVE AGENT IN CYCLIC (COHERENCE) TREATMENT OF OSTEOPOROSIS NOVO NORDISK A/S (DK) 1997-12-11 WO disclosed
WO-1997023508-A1 COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES NOVO NORDISK A/S (DK) 1997-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030055261-A1 Compounds with growth hormone releasing properties GHRHR, GHSR, IGFBP1 MMP9 2831/4885MMP8 4280/4885FCER2 4640/4885
US-20030040483-A1 Compounds with growth hormone releasing properties GHRHR, GHSR, GRPR MMP9 3090/4885MMP8 4276/4885FCER2 4642/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.